GSK_ Annual_Report_2021-22

Notes to the Consolidated Financial Statements for the year ended March 31, 2022 255 ( ` in lakhs ) As at March 31, 2021 (s) Outstanding payables at the period end : GlaxoSmithKline Pte Limited, Singapore 46.17 GlaxoSmithKline Biologicals S.A., Belgium 75,78.57 GlaxoSmithKline Export Limited, U.K. 23,27.92 GlaxoSmithkline Pharma India Pvt Ltd. 1,49.50 GlaxoSmithKline Services Unlimited, U.K. 32.50 GlaxoSmithKline Asia Private Limited, India 17,79.02 SmithKline Beecham Limited, U.K. 26.68 ( ` in lakhs ) As at March 31, 2021 (t) Cross charges recoverable at the period end : GSK India Global Services Private Limited 4.82 (iv) Details relating to persons referred to in item 1(iii) above: ( ` in lakhs ) Year ended March 31, 2022 Year ended March 31, 2021 1 Remuneration/commission/sitting fees 40,41.79 37,93.20 2 Payments under the long-term incentive plan 2,27.62 2,95.47 (v) Disclosure in respect of material transactions with persons referred to in item 1(iii) above: ( ` in lakhs ) Year ended March 31, 2022 Year ended March 31, 2021 (a) Remuneration/commission/sitting fees (Refer Note below): Mr. S. Venkatesh 9,98.38 8,21.46 Mr. A. Iyer - 3,42.86 Mr. R. Krishnaswamy - 5,01.22 Ms. P. Thakur 4,03.70 3,27.63 Ms. M. Priyam - 1,24.19 (b) Payments made during the year under the long-term incentive plan (Refer Note below): Ms. P. Thakur 85.82 27.89 Mr. R. Krishnaswamy - 53.24 Mr. S. Dheri 39.64 26.48 Mr. A. Iyer - 89.16 Mr. B. Kotak - 43.36 Note: Amounts are not comparable as they pertain to part of the year and/ or are recorded on cash payment basis.